Theophylline is commonly used in the treatment of obstructive airway diseases. The identification and functional characterization of different phosphodiesterase (PDE) isoenzymes has led to the development of various isoenzyme-selective inhibitors as potential anti-asthma drugs. Considering the distribution of isoenzymes in target tissues, with high activity of PDE3 and PDE4 in airway smooth muscle and inflammatory cells, selective inhibitors of these isoenzymes may add to the therapy of chronic airflow obstruction. However, initial data from clinical trials with selective PDE3 and PDE4 inhibitors have been somewhat disappointing and have tempered the expectations considerably since these drugs had limited efficacy and their use was clinically limited through side effects. The improved understanding of the molecular biology of PDEs enabled the synthesis of novel drugs with an improved risk/benefit ratio. These 'second generation' selective drugs have produced more promising clinical results not only for the treatment of bronchial asthma but also for the treatment of chronic obstructive pulmonary disease.
Background
Nonselective inhibitors of cyclic nucleotide phosphodiesterase (PDE), such as theophylline, have been used for the treatment of obstructive airways diseases for several decades. Until now, theophylline remains one of the world's most widely used medications for asthma and plays an important role in the treatment of chronic obstructive pulmonary disease (COPD) [1] , despite its relegation from first-line therapy in international guidelines for the treatment of asthma [2] .
The renewed interest in recent years regarding the pharmacology and clinical effects of this class of drugs is based largely on advances in the knowledge and understanding of the PDE isoenzymes, which represent one of theophylline's biochemical targets, and from demonstrations of a range of effects of theophylline in addition to its well characterized bronchodilator property. These additional actions are thought to involve a variety of actions such as the effects on the vasculature in patients with increased pulmonary artery pressure, the suppression of inflammatory cell responses, and the induction of apoptosis of eosinophils.
The immunopharmacology of theophylline has become a particular subject of interest in recent years, and the ability of drugs that inhibit certain PDE isoenzymes (see below) to suppress both immune cell functions in vitro and allergic pulmonary inflammation in vivo, is believed to present an opportunity for the development of novel drugs with antiinflammatory properties through greater selectivity and improved side-effect profile, compared with nonselective drugs such as theophylline.
Although it has been suggested that some of theophylline's adverse effects are due to the drug's non PDE-inhibitory actions, such as antagonism of adenosine receptors, there is now evidence to suggest that the most common sideeffects, including cardiac dysrhythmias and nausea, are also mediated by PDE inhibition.
With this in mind, it was proposed that selective targetting of the PDE isoenzymes involved in regulating cyclic nucleotide levels in cells relevant to asthma and COPD -namely bronchial smooth muscle and the inflammatory cells characteristic of bronchial infiltrates ¹ would allow the beneficial effects of theophylline to be obtained in the absence of cardiovascular, gastrointestinal, and central nervous system side-effects. Many such family-selective or 'second-generation' PDE inhibitors have been developed, some exhibiting selectivity ratios of several thousand for a particular isoenzyme family over all other families.
While it has been widely suggested that increasingly selective PDE4 inhibitors will enable targeted suppression of inflammation, several pharmaceutical companies have followed this course in developing selective drugs for clinical trials in asthma and inflammatory diseases [3] . However, in the past clinical trials with some of the highly selective drugs were disappointing. One reason for this limited success may be the presence of significant amounts of other PDE isoenzymes in addition to PDE4 in the target tissues [4, 5] . Therefore, just as combined inhibition of PDE3 and PDE4 is more effective than inhibition of a single isoenzyme family in relaxing pre-contracted human airways smooth muscle [6, 7] , a more effective suppression of inflammation might also be achieved by the combination of selective PDE inhibitors rather than by a single isoenzyme-selective PDE inhibitor. This report tries to summarize current concepts and available clinical data for selective PDE inhibitors for the treatment of asthma and COPD.
Molecular biology of PDE
Cyclic nucleotide PDE was identified 40 years ago as an ubiquitous enzyme catalysing the breakdown of the intracellular 'second messenger' adenosine 3 0 :5 0 -cyclic monophosphate (cAMP) and guanosine 3 0 :5 0 -cyclic monophosphate (cGMP). Theophylline was recognized as an inhibitor of this enzyme activity and has been shown to exert many of its important therapeutic effects through PDE inhibition. In recent years, PDE has been subject to intense biochemical scrutiny, and is now acknowledged to represent the activity of a large 'superfamily' of enzymes forming at least eight distinct families of isoenzymes that differ in their substrate specificities and affinities and in their sensitivity to stimulation or inhibition by endogenous cofactors and modulators. Theophylline (1,3-dimethylxanthine) inhibits these isoenzymes with roughly equal potency and, in common with several related alkylxanthine compounds such as IBMX (3-isobutyl-1-methylxanthine) and pentoxifylline (1-5-oxohexyl-3-7-dimethylxanthine), is described as a nonselective or 'first generation' PDE inhibitor.
During the last decades, long after the discovery of cyclic AMP and its degrading enzymes, a lot of research concentrated on further characterization of different PDE isoenzymes [8] , their localization, and their involvement in the regulation of different cell functions. In the period from 1970 to 1980, various PDE isoenzymes were defined by differences in substrate specificities and/or regulation characteristics. Subsequently, an extensive research and development effort led to the synthesis, characterization, and clinical study of a series of new compounds that were selective for one or two isoenzymes. These mono-and dual-selective 'second-generation' PDE inhibitors were isoenzyme-targetted, especially to PDE3 and PDE4, and they offered both new clinical uses and the possibility for analyses of the tissue distribution and functional role of individual isoenzymes. It emerged that these compounds exhibited a limited organ specificity and ¹ importantly, from a clinical viewpoint ¹ a therapeutic potential against heart failure and depression. Currently, a variety of new substances are under investigation as alternative potential anti-inflammatory drugs and, if the theoretical concept holds true, agents with lower potential for side-effects are being discovered.
In the meantime, eight PDE isoenzyme gene families have been identified and the list is still likely not to be complete [4, [9] [10] [11] [12] [13] . They not only differ in their substrate specificity, in their affinity, and in their sensitivity to stimulation or inhibition by endogenous cofactors and modulators, but also in their localization in specific organ systems or tissues [12] . Within the airways, PDE4 appears to be the most important isoenzyme because of its distribution in airway smooth muscle and inflammatory cells (Figure 1) . PDE4 has been shown to include the products of four separate genes (PDE4A-D), with variants of PDE4A, 4B, and 4D also occurring through differential mRNA splicing [11] . The expression of the different gene products is heterogeneous and it is striking that PDE4C is rarely expressed in blood-derived cells, including the inflammatory cells implicated in allergic airways obstruction [3, 11] . Most of the selective inhibitors developed so far are substrate-site-directed competitive inhibitors, but a few act at allosteric sites [14, 15] . Drug targetting can focus either on the selectivity for 'subtypes' of the PDE gene families, e.g. PDE4A, 4B, 4C, or 4D [16] , or on one of two conformers of the isoenzyme [17] [18] [19] , since studies support the proposal that two distinct and catalytically active conformers of PDE4 isoenzymes coexist. One of them binds rolipram at the catalytic site with a high affinity ('high-affinity rolipram binding site') and a second binds rolipram with a lower affinity ('low-affinity rolipram binding site') [18, 20] . It is noteworthy that the therapeutic effects appear to be related to the 'low-affinity rolipram binding site', whereas the sideeffects are more likely to be related to the 'high-affinity rolipram binding site'. Second-generation PDE4 inhibitors such as RP73401, CDP840, and SB207499 were specifically designed to have an improved therapeutic index according to the approach described above.
Subtype-selective PDE4 inhibitors have yet to be reported. Although the presence of large amounts of PDE4C in the central nervous system, compared with its absence in leucocytes [21, 22] , suggests that theoretically one promising way forward is to synthesize compounds with decreased activity against this subtype, it is unclear whether inhibiting a single PDE4 subtype will have a great enough impact on total cellular cAMP metabolism to alter cell function meaningfully, and, additionally, inhibition of one subtype might lead to a reciprocal up-regulation of another.
Cellular distribution of PDE isoenzymes
Most studies to date have focused on PDE4 as a potential target for novel anti-inflammatory drugs, since this isoenzyme family is represented in all cells, with the exception of platelets, that are thought to be involved in inflammatory reactions [23] . PDE4, the low Km cAMP-specific isozyme, is the major cAMP-metabolizing enzyme in immune and inflammatory cells, and is one of two major cAMP-metabolizing enzymes in airway smooth muscle. Several inflammatory cell classes have undergone similar investigation, revealing the exclusive presence of PDE4 in neutrophils, eosinophils, basophils, and monocytes, while in macrophages PDE3 and PDE1 and in T lymphocytes PDE7 activity has also been demonstrated [24] [25] [26] .
Furthermore, PDE inhibitors can, for example, inhibit mediator release of inflammatory cells like monocytes and monocyte-derived macrophages [27] , lung mast cells [28, 29] , T lymphocytes [30, 31] , B lymphocytes [32] , alveolar macrophages [33] [34] [35] , and eosinophils [3, 36, 37] .
Smooth muscle
Within human airways, isoenzyme-selective PDE inhibitors were identified that cause effective relaxation of airway smooth muscle [6, 7, [38] [39] [40] . Studies of the PDE isoenzyme profiles of these tissues and cells revealed the presence of enzyme activities of the PDE1, PDE2, PDE3, PDE4, and PDE5 classes [6, 7, 39] , while selective inhibitors of PDE3 and PDE4 have been shown to cause relaxation of bronchial rings under various conditions [7, 38, 41] . Functional analyses of PDE isozymes suggest that PDE3 and PDE4 coregulate cAMP content in human airway smooth muscle. This appears to be the case, because either a combination of PDE3 and PDE4 inhibitors or dual PDE3/ 4 inhibitors produce a much greater bronchorelaxant effect than individual isoenzyme-selective agents alone [6, 39] .
Furthermore, a number of studies support the proposal that cAMP not only is involved in smooth muscle relaxation but also exerts an overall inhibitory influence on airway smooth muscle proliferation [42] [43] [44] [45] . It can modulate airway smooth muscle hypertrophy and hyperplasia, which are common morphological features of chronic asthma [46, 47] . The actions of isoenzyme-selective inhibitors on human airway smooth muscle proliferation have not been investigated; however, in pig aortic smooth muscle the combination of a PDE3 and PDE4 inhibitor, but not the individual inhibitor alone, was shown to have a marked inhibitory effect on proliferation [48] .
Four PDE isoenzyme families, PDE1, PDE3, PDE4, and PDE5, have been found in human pulmonary arteries with high quantities of PDE3 and PDE5 and a smaller amount of PDE4 [49] . Selective inhibitors of PDE3 and PDE5, or combined inhibition of PDE3 and 4, or 3 and 5 exerted relaxation of pulmonary artery rings, whereby these functional results corresponded broadly to the pattern of PDE isozymes found in the pulmonary artery smooth muscle [49] .
Lymphocytes
Homogenates of lymphocytes from the peripheral blood predominantly show PDE3 and PDE4 activities with no difference between CD4 and CD8 positive cells. In addition to its ability to inhibit mitogen-induced and T-cell antigen receptor (CD3)-mediated proliferation of T lymphocytes in vitro [50, 51] , theophylline enhances the suppression of autologous cell proliferation in mixed lymphocyte preparations [52] , a phenomenon that is reflected by the induction in theophylline-treated asthmatic subjects of an increased population of suppressor T cells [53, 54] . Theophylline also reduces cytokine release from T lymphocytes in vitro [51, 55] , which may imply further actions on cytokinedependent functions of other leucocytes in vivo.
Mast cells
Experiments on human lung mast cells suggest that these cells contain PDE3 and PDE4 [25, 56] , since both PDE3 and PDE4 inhibitors reduce antigen-driven histamine release from human lung [57, 58] and skin [58] mast cells.
Neutrophils
In human neutrophils PDE4 is the predominant cAMP-metabolizing enzyme [59] [60] [61] , which is involved in many neutrophil functions and neutrophil responses to stimuli (Figure 2 ). These processes include the stimulation of superoxide anion production by N-formyl-methionyl-leucyl-phenylalanine (fMLP) [59] [60] [61] [62] , C5a [60] , granulocyte-macrophage colonystimulating factor [63] , and TNFa [64] . Furthermore, PDE4 plays an important role in the regulation of fMLP-induced degranulation [65] [66] [67] , leukotriene biosynthesis [61] , and adhesion to endothelial cells [68] . Inhibitory effects can be observed ex vivo on neutrophils from patients treated with theophylline, whose chemotactic responses are reduced compared with cells from untreated patients [69] .
Eosinophils
Human eosinophils contain PDE4 and a broad spectrum of eosinophil functions (Figure 3) 3 . The eosinophil as a potential target in the treatment of bronchial asthma with selective PDE inhibitors [12] . PDE4 is the predominant cAMP-metabolizing enzyme in human eosinophils. PDE4 inhibitors affect proliferation, differentiation, and export of eosinophils from the bone marrow, chemotaxis, adhesion, and transmigration in the blood vessels, and the release of chemotactic and inflammatory mediators from activated cells.
inhibitors such as opsonized zymosan-stimulated superoxide generation [70, 71] , platelet-activating factor (PAF)-and C5a-induced LTC 4 production, as well as chemotaxis [25, 72] . Furthermore, in the presence of a b-adrenoceptor agonist, PDE4 inhibitors reduced the release of eosinophil cationic protein and eosinophil-derived neurotoxin in response to C5a [73] . High concentrations of theophylline suppress reactive oxygen metabolite production by neutrophils and eosinophils but lower concentrations enhance this response [74, 75] . At high concentrations, the survival time of eosinophils in culture is reduced [76] , apparently through the induction of apoptosis, and this may have implications for the maintenance of inflammation in vivo. Other eosinophil functions, such as leukotriene C 4 release, however, are inhibited by low concentrations of theophylline in vitro [77] .
Side effects of PDE inhibitors
Theophylline exerts frequent side effects that can become severe at plasma drug concentrations only slightly higher than those typically required to effect bronchodilation in asthmatic patients. Side effects of theophylline stem from its tendency to inhibit indiscriminately all PDEs in all tissues of the body [78, 79] . The side effects produced by nonselective inhibition limits the degree of enzyme inhibition achievable in target tissues, i.e. airway and vascular smooth muscle as well as immunocompetent cells. The most common side effects, including cardiac dysrhythmias and nausea, are believed to be mediated by PDE inhibition.
Chronotropic effects on the heart, particularly sinus tachycardia [80] , can be caused by the elevation of cAMP levels in cardiac muscle with a subsequent calcium overload [81] or reflecting a reflex reaction to peripheral vasodilation [82] . Theophylline has long been recognized as a diuretic, and an action that results at least in part from increased renal blood flow and glomerular filtration rate. In vivo, however, theophylline treatment can cause electrolytic disturbances, with hypokalaemia being a particular problem [83] . Furthermore, theophylline as well as caffeine, stimulates the central nervous system at relatively low doses in vivo, since the drugs are concentrated in the cerebrospinal fluid [80] . Actions of methylxanthines in the central nervous system include a beneficial increase in ventilatory drive and a general increase in alertness and lessening of fatigue, but also account for the risk of tremor and seizures during theophylline therapy. Effects on the central nervous system are further nausea and vomiting, whereby this action can be mimicked by selective PDE4 inhibitors and apparently results from the inhibition of PDE in the emesis centres of the brain [84] . Another side effect is the increased acid secretion that is believed to be due to inhibition of PDE4 in parietal glands [85] .
PDE3 inhibition can produce a number of cardiovascular side effects [86, 87] that include life-threatening arrhythmias in patients with compromised cardiac function [88] . The cardiovascular activity of dual PDE3/4 inhibitors is likely to be even more marked, since PDE4 inhibitors, although devoid of cardiovascular effects on their own, potentiate the cardiovascular actions of PDE3 inhibitors [89] . Nausea, vomiting, and gastric acid secretion are class effects of firstgeneration PDE4 inhibitors [17] [18] [19] 85, 90, 91] .
Rationale for PDE4 inhibitors in asthma and COPD
Airflow obstruction and airway inflammation are features of asthma as well as COPD. While bronchial asthma is predominantly characterized by an eosinophilic inflammation, neutrophils are believed to play a major role in the pathogenesis of COPD. Therefore, PDE isozymes that are involved in smooth muscle relaxation and are also found in eosinophils as well as neutrophils, are likely to play an important role in both diseases and represent an obvious target for new therapeutic strategies. The development of selective PDE-inhibiting substances might have additional clinical relevance, minimizing side effects that are seen in patients treated with nonselective inhibitors such as theophylline.
It has been suggested that many of theophylline's adverse effects, including cardiac dysrhythmias and nausea, are due to the drug's nonselective PDE inhibition. In addition to theophylline's relatively low efficacy, it was proposed that selective targetting of the PDE isoenzymes involved in regulating cyclic nucleotide levels in cells relevant to asthma and also COPD -namely bronchial smooth muscle and the inflammatory cells characteristic of bronchial infiltrates ¹ would allow the beneficial effects of theophylline to be obtained in the absence of cardiovascular, gastrointestinal, and central nervous system side effects.
The ability of PDE4 inhibitors both to relax airway smooth muscle on one hand and to suppress the function of a range of inflammatory cells on the other, led to a concentration of the research effort on drugs of this class. Selective PDE4 inhibitors have been demonstrated to exert suppressive action on neutrophil and eosinophil function in vitro that resembles the action of high concentrations of theophylline [61, 70, 77] , with the added benefit of exhibiting none of the actions of theophylline that are assumed to result from that drug's adenosine antagonistic action [74, 75] . In vivo, PDE4 inhibitors reduce the influx of eosinophils to the lungs of allergen-challenged animals in a manner similar to that displayed by theophylline, whilst also reducing the bronchoconstriction and elevated bronchial responsiveness occurring after allergen challenge [92] [93] [94] . These effects can be seen in the absence of cardiovascular effects such as tachycardia, although emetic and other unwanted gastroSelective phosphodiesterase inhibitors 103 intestinal effects persist with some of these drugs [91, 95] . PDE4 inhibitors also suppress the activity of immune cells, including CD4
þ T-lymphocytes, monocytes, mast cells, and basophils. These agents also reduce pulmonary oedema in animal models, inhibit eNANC activity, potentiate iNANC activity, have been reported to reduce airway smooth muscle mitogenesis, and induce bronchodilation.
PDE4 inhibitors also suppress the activity of a number of inflammatory cells associated with the pathophysiology of COPD, including monocytes/macrophages, CD8 þ T lymphocytes, and neutrophils. PDE4 inhibitors also reduce vascular smooth muscle mitogenesis and, potentially, alter the ability of airway epithelial cells to generate pro-inflammatory mediators. Through the release of neutral proteases and acid hydrolases from their granules and the generation of reactive oxygen species, neutrophils contribute to tissue destruction associated with chronic inflammation and are implicated in the pathology of conditions such as emphysema [96] .
Clinical trials in asthma
In summarizing the available clinical data on selective PDE inhibitors for asthma and COPD, it becomes apparent that there is a significant imbalance between the increased knowledge of the molecular biology of PDE, including the performed in vitro experiments, and larger clinical trials. While there are a few data to be reported in the field of asthma, the experience in COPD is even more scarce and larger clinical trials are just about to begin.
Earlier studies with selective PDE3 inhibitors such as milrinone, have demonstrated that these drugs induce shortlived bronchodilation and some minor degree of protection against induced bronchoconstriction [97, 98] . These compounds, which were developed as cardiotonic agents on the basis of their profound effects in the cardiovascular system [99] , produced marked side effects, such as tachycardia, hypotension, and headache [97, 98] , and appeared unlikely to be of benefit in the therapy of obstructive lung diseases.
A preliminary and early report of the actions of a weak selective PDE4 inhibitor, tibenelast (LY 186,655), described a slight and statistically nonsignificant increase in baseline forced expiratory volume in 1 s (FEV 1 ) in asthmatic subjects [100] , while clinical trials which were performed with the PDE5 selective inhibitor zaprinast showed that oral administration of the compound reduced exercise-induced bronchoconstriction in adult asthmatics. Surprisingly, in the some studies the drug had no effect on histamine-induced bronchoconstriction in the same subjects [101] , nor did it affect exercise-induced bronchoconstriction in children [102] .
Further clinical data were obtained with dual PDE3/4 selective inhibitors, but the results obtained with drugs such as zardaverine and benafentrine were inconclusive.
Inhalation, but neither oral nor intravenous application, of benafentrine by normal volunteers resulted in bronchodilation [103] . Zardaverine produced a modest and short-lived bronchodilation in a small group of 12 asthmatic patients, which was significant only during the first hour after administration (Figure 4a) . The drug was given by inhalation and patients inhaled 1.5 mg of zardaverine four times at 15-min intervals [104] .
Recently, the efficacy and safety of a novel selective PDE4 inhibitor, SB 207,499 (Ariflo TM ), in asthma was Fig. 4 . Effect of the dual PDE3/4 inhibitor zardaverine on baseline lung function in patients with (a) bronchial asthma [104] and (b) COPD [107] . Compared with placebo, zardaverine given by inhalation produced modest bronchodilation in asthmatic patients (a), whereas no effect on lung function was observed in patients with COPD (b). FEV 1 , forced expiratory volume in 1 s. explored in a 6-week placebo-controlled dose-ranging study in patients taking concomitant inhaled corticosteroids. Three hundred and three patients were treated with oral SB 207,499 at dosages of 5, 10, or 15 mg b.i.d., or placebo, for 6 weeks. In patients receiving 15 mg b.i.d., there was a 160-mL mean difference in trough FEV 1 compared with placebo at the end of the study, which did not quite reach statistical significance. The increase in trough FEV 1 was evident at week 1 and was significantly different from placebo at week 2 (mean difference 210 mL; P ¼ 0.006).
Trends for improvements were also seen for other pulmonary function tests, including PEFR and FEF . Interestingly, the effects of SB 207,499 on FEV 1 and PEFR were greater in patients taking less inhaled steroids. A double-blind, placebo-controlled study has been made of another potent, selective PDE4 inhibitor, CDP840, which showed a suppression of late reactions to inhaled allergen after 9.5 days' oral administration. The late reaction, measured as area under the curve, was inhibited by 30% in a group of 14 asthmatics with no effect on the early response to allergen ( Figure 5 ). Interestingly, two other studies performed in parallel demonstrated that this drug given orally at doses of 15 and 30 mg had no effect on baseline lung function or histamine-induced bronchoconstriction in patients with asthma [105] .
Clinical data in COPD
Information from clinical trials with isoenzyme-selective PDE inhibitors in patients with COPD is still very limited. At this time only very few published data exist on the treatment of COPD with selective PDE inhibitors, while several larger studies are being performed at present. Pulmonary hypertension is observed in patients with severe COPD and oral administration of the selective PDE3 inhibitor, milrinone, decreases mean pulmonary artery pressure under clinical conditions [106] . Furthermore, the selective PDE3 inhibitor, enoximone (MDL 17043), was shown to reduce pulmonary hypertension and airway resistance in patients hospitalized with decompensated COPD [97] . The fact that selective PDE3 inhibitors are able to exhibit these effects is in accordance with in vitro findings demonstrating that selective inhibition of PDE3 and 5, or combined inhibition or PDE 3 and 4 or 3 and 5, exerted relaxation of pulmonary artery rings, corresponding broadly to the pattern of PDE isozymes found in the pulmonary artery smooth muscle [49] . Selective PDE3 inhibition by motapizone, and PDE5 inhibition by zaprinast, decreased pulmonary artery pressure to the same extent, whereas PDE4 inhibition was less effective. Although these in vitro data suggested a marked effect of PDE3/4 and most notably PDE3/5, no studies with these combinations have so far been reported.
In a randomized, double blind and placebo-controlled phase II clinical trial, 10 patients with chronic airflow obstruction were investigated to assess the effect of the dual PDE3/4 inhibitor zardaverine [107] . The study medication was given by MDI at three different doses and the effect on FEV 1 measured by spirometry was assessed at 10-min intervals for the first hour, and at 30-min intervals for 3 h after medication. In contrast to the findings obtained in patients with bronchial asthma, the inhalation of zardaverine had no bronchodilatory effect in these patients with COPD, although it was demonstrated in the same study that the subjects responded to inhalation of 300 mg salbutamol with a significant increase in forced expiratory volume (Figure 4b) .
The selective second-generation PDE4 inhibitor, Ariflo TM (SB 207,499), is currently under investigation also as a potential therapy for obstructive lung disease. The first study performed by Murdoch et al. [108] was a randomized double-blind, placebo-controlled, parallel group study to assess the safety and tolerability of single and repeat oral doses of SB 207,499. At doses up to and including 15 mg b.i.d. this PDE4 inhibitor was safe and well tolerated; however, at a dose of 20 mg given as a single dose, relevant side effects such as nausea and vomiting occurred.
The efficacy and safety of SB 207,499 in COPD was then evaluated in a randomized, placebo-controlled study [109] . Four hundred and twenty-four patients with COPD were randomized to receive Ariflo TM at dosages of 5, 10, or 15 mg b.i.d., or placebo, for 6 weeks. Patients in this trial had moderate to severe airflow obstruction with an FEV 1 at baseline of 46.8% predicted normal, and a FEV 1 :FVC ratio of 55%. Notably, they were only partially reversible with a mean acute responsiveness to salbutamol of 5.4%, and had a mean smoking history of 39.7 pack years. In the group of patients receiving Ariflo TM 15 mg b.i.d., a progressive improvement in trough clinic FEV 1 was observed, beginning in 1 week and reaching a maximum mean difference compared with placebo of 160 mL (P < 0.001) at week 6, representing an 11% improvement. Similar trends were observed for trough FVC and PEFR, with maximum mean differences compared with placebo observed at week 6 of 190 mL (P < 0.001) and 34.1 L/min (P < 0.001), respectively. In addition, consistent improvements relative to placebo were observed for the 15 mg b.i.d. dose in exertional dyspnoea, rescue bronchodilator use, and resting and postexercise SaO 2 .
Conclusions
The importance of PDE in the regulation of cell function is increasingly recognized, and in the past this has led to several programmes of synthesis of novel PDE inhibitors ¹ of varying isoenzyme selectivity ¹ as potential antiasthma drugs. Data from clinical trials with the first selective drugs have been disappointing and have tempered the expectations considerably, since these drugs had limited efficacy and their use was significantly limited through side effects. The improved understanding of the molecular biology of PDEs together with a continued effort to specifically target novel drugs to improve the risk/benefit ratio has now resulted in second-generation drugs that have produced more promising clinical results that seem to justify the wide research efforts in the past. Probably even more importantly, selective inhibitors of PDE4 are now also under clinical investigation for COPD and the results so far are promising that this class of drug may add to the therapy of chronic airflow obstruction. If confirmed in larger and more detailed trials this may turn out to be of particular importance, since the existing drug therapy, including steroids, has so far failed to alter significantly the course of the disease in chronic treatment.
